Focal prostate therapy is drifting outside the guideline that calls it experimental

Two data points landed within a month of each other and they point in opposite directions. A U.K. study reported that 10 years after focal therapy for localized prostate cancer, 0.1% of treated men had died of prostate cancer, comparable to survival after standard treatment, with higher satisfaction and lower rates of side effects ^[4]; a paper published last week found that half of the patients actually receiving focal therapy had either higher-risk or lower-risk disease than the guidelines contemplate, including men whom guidelines say need no immediate treatment and should be on active surveillance ^[7].

The clinical case for the approach is not complicated. For prostate cancer, treatment is usually all or nothing: outside low-grade disease unlikely to turn deadly, the whole gland is removed or irradiated, and the long-term consequences include incontinence and erectile dysfunction ^[1]. Focal therapy instead targets lesions visible on MRI, using technologies that heat, freeze, burn, or electrocute the tissue, often in a single session and sometimes in a doctor's office ^[2]. The hardware is not new; these technologies date to the late 1990s, and what changed is MRI good enough to locate a lesion, which is why the topic dominated the recent annual meeting of urologists ^[3].

The American Urological Association still labels focal therapy experimental. It acknowledges it as an option for intermediate-risk cancer while stating it should be performed only within studies and prospective registries ^[6]. Under those guidelines roughly 10% to 20% of prostate cancer cases would qualify ^[8]. Recent U.S. data show 1.3% of prostate cancer patients receive focal therapy ^[9], which is somewhere between about 7% and 13% of the eligible pool ^[17]. So the adoption problem is not volume. It is indication: applying last week's finding to the national rate implies roughly 0.65% of all U.S. prostate cancer patients are being ablated outside the risk band the guideline endorses ^[15].

The modality mix shows how fast practice moves on its own. Focal therapy is a set of FDA-authorized ablation technologies, with cryotherapy, laser ablation, and high intensity focused ultrasound the most common, chosen by the shape and location of the lesion ^[13]. Cryotherapy was nearly 80% of focal procedures in 2010 and 20% by 2023, while laser ablation was about 45% and HIFU, the fastest growing, was 35% ^[14]. That is a roughly 60 point collapse in the oldest method's share in 13 years ^[16], and the three together account for essentially all 2023 procedures ^[18].

Payment is where the label bites. Many leading cancer centers and independent physicians offer focal therapy, patients report high satisfaction, and commercial insurers often do not cover it ^[10]; Medicare does ^[11]. Chris Brosseau, 48, of Denver, with a family history of aggressive prostate cancer, told STAT he chose focal therapy over surveillance, surgery, and radiation at about $17,000 out of pocket, said he is "super happy with it" with "zero side effects," and would repeat it if the cancer returns on the other side ^[12].

Watch for randomized trials comparing focal therapy directly against standard of care, which is what the skeptical half of the specialty says it needs ^[5]. Until those exist, the practical questions are whether the AUA moves off "experimental," whether registry enrollment tightens who gets treated, and whether commercial payers follow Medicare.